CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 60.21 CNY -1.67%
Market Cap: 6.9B CNY
Have any thoughts about
CanSino Biologics Inc?
Write Note

CanSino Biologics Inc
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CanSino Biologics Inc
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
CanSino Biologics Inc
SSE:688185
Long-Term Investments
ÂĄ446.6m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Long-Term Investments
ÂĄ684.7m
CAGR 3-Years
189%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Long-Term Investments
ÂĄ571.9m
CAGR 3-Years
-14%
CAGR 5-Years
-8%
CAGR 10-Years
-1%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Long-Term Investments
ÂĄ1.5B
CAGR 3-Years
-10%
CAGR 5-Years
53%
CAGR 10-Years
77%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Long-Term Investments
ÂĄ12.7B
CAGR 3-Years
122%
CAGR 5-Years
27%
CAGR 10-Years
68%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Long-Term Investments
ÂĄ1.6m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CanSino Biologics Inc
Glance View

Market Cap
6.9B CNY
Industry
Pharmaceuticals

CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Intrinsic Value
100.07 CNY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is CanSino Biologics Inc's Long-Term Investments?
Long-Term Investments
446.6m CNY

Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's Long-Term Investments amounts to 446.6m CNY.

What is CanSino Biologics Inc's Long-Term Investments growth rate?
Long-Term Investments CAGR 3Y
19%

Over the last year, the Long-Term Investments growth was 791%. The average annual Long-Term Investments growth rates for CanSino Biologics Inc have been 19% over the past three years .

Back to Top